# ALX Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alx-oncology

- Industry: Biotechnology
- Headquarters: Burlingame, US
- Website: www.alxoncology.com
- Total disclosed funding: $141M
- Latest round: Series C (Feb 7, 2020)
- Investors on record: 11

## About

ALX Oncology Limited is a biotechnology company concentrated on developing advanced immuno-oncology therapies that aim to enhance the immune system's ability to fight cancer.Founded in 2015 and headquartered in Burlingame, US, ALX Oncology Limited specializes in creating innovative therapies for oncology. The company was established by Kipp Weiskopf. ALX has successfully raised a total of USD 47.03 mn in funding, most recently through a Private Placement/Follow on on October 4, 2023, which marks their sixth deal. The company's efforts in fundraising have consistently targeted the advancement of their flagship product, evorpacept.ALX Oncology primarily focuses on developing innovative immuno-oncology therapies aimed at enhancing the body’s immune response to cancer. Their lead product, evorpacept, is designed to optimize the current treatment landscape by serving as a cornerstone therapy for various cancer types. This therapeutic candidate has undergone clinical validation, showcasing its potential to improve patient outcomes by boosting immune system functionality against tumors. The company targets a diverse patient population, particularly those battling various forms of cancer across multiple geographical markets, including North America, Europe, and Asia. Through collaborations and clinical trials, ALX Oncology aims to reach healthcare providers and institutions that treat cancer patients, thereby addressing significant unmet medical needs within the oncology sector.In 2020, ALX Oncology reported revenue of USD 1,182,000 and an EBITDA loss of USD 141,595,000 for the same year. Their revenue generation operates primarily through clinical partnerships and collaborations with pharmaceutical companies and research institutions, focused on advancing their flagship product, evorpacept. Transactions typically involve structured agreements where partners may contribute to research and development costs in exchange for shared rights or royalties on future sales, aligning their revenue model closely with the value imparted by their innovative therapies.ALX Oncology's strategy for future growth includes the development of ALX148, a next-generation CD47 myeloid checkpoint inhibitor, which is being designed for use in combination with anti-cancer therapeutics. The company aims to expand its offerings into additional solid tumors and hematologic indications. The recent funding of USD 47.03 mn will support these initiatives, alongside funding for clinical trials and working capital. ALX Oncology plans to leverage these resources to enhance their product pipeline and improve access to new markets.

## Funding rounds

- Series C, Feb 7, 2020, $105M — HBM Partners, Vivo Capital, Foresite Capital, VenBio, Lightstone Ventures, BVF Partners, Cormorant Asset Management, Janus Henderson Investors, Logos Capital
- Series A, Mar 18, 2015, $36M — Stanford University, VenBio, Lightstone Ventures, The Longevity Fund

## Investors

- Stanford University — Series A
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series C
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series A, Series C
- The Longevity Fund (https://capitalatlas.ai/funds/the-longevity-fund) — Series A
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Janus Henderson Investors — Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series C